About Synthetic Genomics
Synthetic Genomics is a Healthcare company based in San Diego (United States) founded in 2005. Synthetic genomic solutions are provided for research and bioproduction markets. Synthetic Genomics has raised $75 million across 4 funding rounds from investors including HHS, Biotechonomy and Draper Frontier. The company has 190 employees. Synthetic Genomics has completed 1 acquisition, including Febit. Synthetic Genomics offers products and services including Algae Biofuel. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its legal entity is SYNTHETIC GENOMICS, INC. Its competitors include Amyris, Avidity Biosciences and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
Synthetic Genomics (SGI) engages in synthesizing and programming DNA by developing and utilizing the technologies in synthetic genomics. SGI provides solutions to three end markets: research, bioproduction and applied products. Its research segment is focused on genomics solutions for academic and commercial RD organizations. Its commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software. In 2015, the company launched the BioXP 3200 system, a benchtop DNA printer that takes sequencing data and produces high-quality DNA fragments. It is also focussed on improving existing production hosts and developing new synthetic production hosts for new and more efficient routes to bioproducts including materials, chemicals, energy and other goods derived from renewable biological resources.
- Headquarters San Diego, United States
- Employees 190
- SectorsHealthcare
- Website syntheticgenomics.com
- Social LinkedIn Facebook
- Legal Name Synthetic Genomics, Inc.
Products & Services of Synthetic Genomics
Synthetic Genomics offers a comprehensive portfolio of products and services, including Algae Biofuel.
Optimizes microalgae to create renewable oil for decarbonizing transportation.
Funding Insights of Synthetic Genomics
Synthetic Genomics has successfully raised a total of $75M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $387.63 thousand completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75M
- Total Rounds 4
- Last Round Grant — $387,632
- First Round $30M
(Dec 2005)
- Investors Count 3
All 4 funding rounds of Synthetic Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2015 | $387,632 | Grant | – | – | |
| Feb 2013 | $10M | Series C | – | – | – |
| Dec 2010 | $35M | Series C | – | – | – |
| Dec 2005 | $30M | Series B | – | Biotechonomy, Draper Frontier | – |
3 investors in total: 3 institutional.
Investors in Synthetic Genomics
Synthetic Genomics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Biotechonomy and Draper Frontier.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| biotechonomy.com | ||||
Seed & early-stage micro VC firm investing in the US | draperfrontier.com | Los Angeles, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Synthetic Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Synthetic Genomics
30 people are tracked at Synthetic Genomics (7 in leadership, 7 in board & advisors, 16 in team); the tracked headcount is 190.
| Name | Role | Group |
|---|---|---|
Oliver Fetzer | CEO | Leadership |
Rob Brown | Vice President, Research | Leadership |
Margaret Dunbar | Vice President, Intellectual Property | Leadership |
Arthur Hodel | Director of Facilities and Environmental Health & Safety | Leadership |
Kelly T. C. | Director of Information Technology & Security | Leadership |
Doug Miller | Chief Financial Officer | Leadership |
Mary Poggi | Executive Assistant to CEO, CFO, COO | Leadership |
David Kiernan | Board Member | Board & advisors |
Kok-Thay Lim | Board Member | Board & advisors |
Barry Schuler | Board Member | Board & advisors |
Reinhard J. Ambros | Board Member | Board & advisors |
Juan Enriquez | Board Member | Board & advisors |
Tina Nova | Board Member | Board & advisors |
Edgardo Cantu | Board Member | Board & advisors |
John Gill | Sr. Automation Program Manager | Team |
Rob Cutler | General Counsel, Corporate Secretary | Team |
Tim Schaller | DevOps Architect | Team |
Trevor Leach | Sr. Software Engineer II | Team |
Eduardo Bracamonte | Facilities Specialist | Team |
Jennifer N. | Program Manager | Team |
10 more people are available in the full profile.
Complete people profiles for Synthetic Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synthetic Genomics
Synthetic Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Febit.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Geniom platform and services are provided for genomic researchers. | febit.com | Wroclaw, Poland | 2005 | Sep 2012 | •••• |
Complete acquisition details for Synthetic Genomics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Synthetic Genomics
4 dated milestones of Synthetic Genomics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Synthetic Genomics is founded.
- Funding First funding round of $30.0M.
- Acquisition Acquires Febit.
- Funding Latest funding round, Grant, of $388K.
Competitors of Synthetic Genomics
Synthetic Genomics has 3 listed competitors in our database, 3 of them funded. They include Amyris, Avidity Biosciences and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of Synthetic Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Synthetic Genomics
Websites that share an audience with Synthetic Genomics (syntheticgenomics.com).
Websites whose visitors overlap most with Synthetic Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| jcvi.org | 100% | 51.2K | #697,057 | View details | |
energybiosciencesinstitute.org | energybiosciencesinstitute.org | 99% | #6,242,856 | – | |
| gene.com | 64% | 492.6K | #97,838 | View details | |
en.wikipedia.org | en.wikipedia.org | 35% | – | ||
| sapphireenergy.com | 34% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Synthetic Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Synthetic Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synthetic Genomics
Complete news archive for Synthetic Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synthetic Genomics
Synthetic Genomics was founded in 2005.
Synthetic Genomics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Synthetic Genomics is a funded company, having raised a total of $75M across 4 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Dec 2005.
Synthetic Genomics has 190 employees.
Synthetic Genomics (SGI) engages in synthesizing and programming DNA by developing and utilizing the technologies in synthetic genomics. SGI provides solutions to three end markets: research, bioproduction and applied products. Its research segment is focused on genomics solutions for academic and commercial RD organizations. Its commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software. In 2015, the company launched the BioXP 3200 system, a benchtop DNA printer that takes sequencing data and produces high-quality DNA fragments. It is also focussed on improving existing production hosts and developing new synthetic production hosts for new and more efficient routes to bioproducts including materials, chemicals, energy and other goods derived from renewable biological resources.
Synthetic Genomics's top competitors include Avidity Biosciences, Amyris and AskBio.
Synthetic Genomics offers Algae Biofuel.
Synthetic Genomics has made 1 acquisition, including Febit.
Synthetic Genomics has 3 investors. Key investors include HHS, Biotechonomy, and Draper Frontier.
Synthetic Genomics operates through Synthetic Genomics, Inc..